Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11002882 | 0.84 | MAPK1 (0.33) | SLC6A2MAPK1KCNH2 | |
| SCHEMBL7109903 | 0.79 | AOC3 (0.44) | SLC6A2SLC6A4GPR84 | |
| SCHEMBL11004428 | 0.75 | PPARG (0.36) | SLC6A2MAPK1KCNH2 | |
| SCHEMBL9200434 | 0.73 | TSHR (0.44) | GPR84 | |
| SCHEMBL11002884 | 0.72 | ALDH1A1 (0.36) | SLC6A2SLC6A4 | |
| SCHEMBL9572562 | 0.71 | AOC3 (0.43) | SLC6A4 | |
| SCHEMBL2422880 | 0.71 | ADRA2A (0.33) | SLC6A2MAPK1KCNH2 | |
| SCHEMBL9572511 | 0.70 | KDM4E (0.43) | SLC6A4 | |
| SCHEMBL1432767 | 0.68 | AOC3 (0.39) | SLC6A2SLC6A4KCNH2GPR84 | |
| SCHEMBL9572839 | 0.68 | PPARG (0.44) | SLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778956-B2 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-7582649-B2 | Oral administration of a dosage of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and a carrier; opiod receptor-like-1 G-protein coupled receptor inhibitors; psychological disorders; nervous system disorders; antidiabetic agents | JANSSEN PHARMACEUTICA, NV (BE) | 2009-09-01 | — | — | US | disclosed |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | BATTISTA KATHLEEN | 2009-05-14 | — | — | US | disclosed |
| US-20060030577-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | BATTISTA KATHLEEN | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030577-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, ADRA1D, OPRD1 | ELANE 2034/4885SLC6A2 707/4885SLC6A4 408/4885 |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | OPRL1, ADRA1D, OPRD1 | ELANE 2034/4885SLC6A2 707/4885SLC6A4 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.